Theriva Biologics, Inc.
Follow $TOVX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $TOVX by emailVeridion Score
BETALOW CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is TOVX moving today?
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
TOVX overview
Related filings and maps
Congress activity in TOVX
No receipt-qualified Congressional disclosure is present for TOVX in the cached public ledger.
TOVX contract awards, year to date.
Public federal awards linked to this ticker.
TOVX lobbying filings, year to date.
Registered lobbying filings matched to Theriva Biologics, Inc..